A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) harboring the T790M resistance mutation, detected from circulating tumor DNA (ctDNA) with unknown tumor mutation status. Materials and Methods To extract ctDNA from plasma, 15 mL of peripheral blood was withdrawn and centrifuged immediately before storage. Cobas ver. 2 and PANA Mutyper were used for ctDNA genotyping. Patients with T790M, detected from ctDNA, were enrolled and they received a oncedaily administration of osimertinib 80 mg. The primary endpoint was objective response rate (ORR), and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety. Results Eighty patients with acquired resistance to prior EGFR-TKI therapies were screened. ctDNA of 21 patients showed T790M positivity, and 19 patients were enrolled. In the responseevaluable population (n=15), ORR was 66.7% (10/15). Median PFS was 8.3 months (95% confidence interval [CI], 7.9 to 8.7) and median DoR was 6.8 months (95% CI, 5.3 to 8.3) in the intent-to-treat population (n=19). No subject experienced drug-related adverse event of grades 3 or required dose reduction. The sensitivity of the ctDNA tests was 56.8% using both methods and 45.9% with either method from the estimated T790M-positive cases. Conclusion Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy.
Abstract
Purpose Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) harboring the T790M resistance mutation, detected from circulating tumor DNA (ctDNA) with unknown tumor mutation status. Materials and Methods To extract ctDNA from plasma, 15 mL of peripheral blood was withdrawn and centrifuged immediately before storage. Cobas ver. 2 and PANA Mutyper were used for ctDNA genotyping. Patients with T790M, detected from ctDNA, were enrolled and they received a oncedaily administration of osimertinib 80 mg. The primary endpoint was objective response rate (ORR), and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety. Results Eighty patients with acquired resistance to prior EGFR-TKI therapies were screened. ctDNA of 21 patients showed T790M positivity, and 19 patients were enrolled. In the responseevaluable population (n=15), ORR was 66.7% (10/15). Median PFS was 8.3 months (95% confidence interval [CI], 7.9 to 8.7) and median DoR was 6.8 months (95% CI, 5.3 to 8.3) in the intent-to-treat population (n=19). No subject experienced drug-related adverse event of grades 3 or required dose reduction. The sensitivity of the ctDNA tests was 56.8% using both methods and 45.9% with either method from the estimated T790M-positive cases. Conclusion Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy.
참고문헌 (22)
- Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
- Janne PA, "AZD9291 in EGFR inhibitor-resistant nonsmall-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
- Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer : AURA study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)
- Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
- Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Ricciuti B, "Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive nonsmall cell lung cancer : rationale, evidence and place in therapy", Ther Adv Med Oncol, 9, pp.387~404 (2017)
- Crowley E, "Liquid biopsy : monitoring cancer-genetics in the blood", Nat Rev Clin Oncol, 10, pp.472~484 (2013)
- Douillard JY, "Gefitinib treatment in EGFR mutated caucasian NSCLC : circulating-free tumor DNA as a surrogate for determination of EGFR status", J Thorac Oncol, 9, pp.1345~1353 (2014)
- Qiu M, "Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer : a meta-analysis", Cancer Epidemiol Biomarkers Prev, 24, pp.206~212 (2015)
- Thress KS, "EGFR mutation detection in ctDNA from NSCLC patient plasma : a cross-platform comparison of leading technologies to support the clinical development of AZD9291", Lung Cancer, 90, pp.509~515 (2015)
- Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
- Jenkins S, "Plasma ctDNA Analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer", J Thorac Oncol, 12, pp.1061~1070 (2017)
- Jackman D, "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer", J Clin Oncol, 28, pp.357~360 (2010)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Kawamura T, "Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure", Cancer Sci, 107, pp.1001~1005 (2016)
- Sundaresan TK, "Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive bloodbased analyses", Clin Cancer Res, 22, pp.1103~1110 (2016)
- Kawamura T, "Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer", Clin Lung Cancer, 19, pp.e247~e252 (2018)
- Ballard P, "Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity", Clin Cancer Res, 22, pp.5130~5140 (2016)
- Goss G, "CNS response to osimertinib in patients with T790Mpositive advanced NSCLC : pooled data from two phase II trials", Ann Oncol, 29, pp.687~693 (2018)
- Mok T, "CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3)", J Clin Oncol, 35(15 Suppl), pp.9005~ (2017)
- Yang JC, "Osimertinib activity in patients (pts) with leptomeningeal (LM)disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study", J Clin Oncol, 34(15Suppl), pp.9002~ (2016)
- Sacher AG, "Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer", JAMA Oncol, 2, pp.1014~1022 (2016)